Covered recipient · General Payments record
REGAN D ROSTORFER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$54.51
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $42.59 | 2 |
| Education | $11.92 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $23.77 | 1 |
| Genentech USA, Inc. | $18.82 | 1 |
| Gilead Sciences, Inc. | $11.92 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
REGAN D ROSTORFER
NPI 1790936409 · CMS profile ID 1154649
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
OCOEE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790936409?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- REGAN D ROSTORFER, NPI 1790936409, CMS profile ID 1154649. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790936409?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). REGAN D ROSTORFER, NPI 1790936409, CMS profile ID 1154649. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790936409?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- REGAN D ROSTORFER, NPI 1790936409, CMS profile ID 1154649, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1790936409?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $54.51 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $18.82 | 12/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835966177 | CMS |
| Gilead Sciences, Inc. | $11.92 | 06/01/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845878569 | CMS |
| Daiichi Sankyo Inc. | $23.77 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836287463 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2024 | Principal investigator | $1,056.76 | 2 |
| PY2023 | Principal investigator | $11,729.09 | 8 |
| PY2022 | Principal investigator | $4,149.79 | 4 |
| PY2021 | Principal investigator | $48,763.81 | 18 |
| PY2020 | Principal investigator | $16,661.10 | 12 |
| PY2019 | Recipient | $5,460.00 | 1 |
| PY2019 | Principal investigator | $29,941.70 | 9 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
18 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,779.87 | 12/31/2021 | Covered Recipient Teaching Hospital Orlando Health | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy | No dispute reported | 06/30/2026 | 848744485 |
| Principal investigator 1 | Gilead Sciences, Inc. | $750.00 | 11/15/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522163 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,250.00 | 08/23/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522161 |
| Principal investigator 1 | ABBVIE INC. | $3,620.00 | 07/23/2021 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) | No dispute reported | 06/30/2026 | 792393357 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 06/23/2021 | Covered Recipient Teaching Hospital ORLANDO HEALTH | PALBOCIBLIB FULVESTRANT IPATASERTIB PH3 STUDY IN 1L HR HER2 MBC | No dispute reported | 06/30/2026 | 835921987 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 06/21/2021 | Covered Recipient Teaching Hospital ORLANDO HEALTH | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) | No dispute reported | 06/30/2026 | 792393343 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,000.00 | 05/24/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522159 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 04/21/2021 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS8201-A-U303 | No dispute reported | 06/30/2026 | 835061619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $800.00 | 04/16/2021 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS8201-A-U303 | No dispute reported | 06/30/2026 | 835061583 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,490.31 | 03/29/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522157 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,763.16 | 03/22/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522155 |
| Principal investigator 1 | Genentech, Inc. | $13,750.00 | 03/02/2021 | Covered Recipient Teaching Hospital ORLANDO HEALTH | PALBOCIBLIB FULVESTRANT IPATASERTIB PH3 STUDY IN 1L HR HER2 MBC | No dispute reported | 06/30/2026 | 835921981 |
| Principal investigator 1 | Radius Health, Inc. | $800.00 | 03/01/2021 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER | No dispute reported | 06/30/2026 | 830710680 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,754.93 | 02/22/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522153 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,315.61 | 01/25/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 01/14/2021 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | Not supplied | No dispute reported | 06/30/2026 | 835055425 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,099.93 | 01/11/2021 | Covered Recipient Teaching Hospital Orlando Health | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | No dispute reported | 06/30/2026 | 803522149 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $90.00 | 01/06/2021 | Non-covered Recipient Entity UF HEALTH CANCER CENTER AT ORLANDO HEALTH | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA) MUTATION OR PHOSPHATASE AND TENSIN HOMOLOG PROTEIN (PTEN) LOSS WITHOUT PIK3CA MUTATION | No dispute reported | 06/30/2026 | 800647145 |